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ﬁ  ndings on the mechanisms of endothelial dysfunction in 
diabetes, which could contribute to the development of 
new treatment options are discussed.
PHYSIOLOGIC ROLE OF THE VASCULAR 
ENDOTHELIUM
The healthy endothelial monolayer is optimally positioned 
in order to respond to physical and chemical signals, by 
producing a wide range of factors that regulate vascular 
tone, cellular adhesion, thromboresistance, smooth 
muscle cell proliferation, and vessel wall inﬂ  ammation. 
The importance of the endothelium was ﬁ  rst recognized 
by its effect in limiting the vascular tone.[9] The vascular 
endothelium also regulates blood ﬂ  ow and, limits leukocyte 
adhesion and platelet aggregation by producing nitric 
oxide (NO), prostacyclin, and ectonucleotidases. As such, 
inﬂ  ammatory activity in the vessel wall is blunted. In 
addition, the endothelium regulates vascular permeability to 
nutrients, macromolecules, and leukocytes; limits activation 
of the coagulation cascade by the thrombomodulin/
protein C, heparin sulfate/antithrombin, and tissue factor/
tissue factor pathway inhibitor interactions; and regulates 
ﬁ  brinolysis by producing tissue activator of plasminogen 
(t-PA) and its inhibitor, PAI-1.[10] 
INTRODUCTION
According to the World Health Organization, diabetes 
mellitus now affects about 220 million people worldwide,[1] 
and the growth in its prevalence represents a global health 
crisis already accounting for more than 10% of the total 
healthcare expenditure in many countries.[2] In the USA, 
over 24 million children and adults (almost 8% of the 
entire population) have diabetes, whereas another 57 
million have prediabetes and are thus likely to develop 
the disease unless they make lifestyle changes.[3] Diabetes 
without proper treatment can cause many complications, 
with cardiovascular diseases accounting for up to 80% of 
premature mortality.[4] 
The endothelium, once considered a mere selectively 
permeable barrier between the bloodstream and the 
outer vascular wall, is now recognized to be a crucial 
homeostatic organ, fundamental for the regulation of 
the vascular tone and structure.[5] Therefore, endothelial 
dysfunction during diabetes has been associated with a 
number of pathophysiologic processes.[6] A considerable 
body of evidence in humans indicates that endothelial 
dysfunction is closely associated with the development of 
diabetic retinopathy,[7] nephropathy, and atherosclerosis in 
both type 1 and type 2 diabetes.[8] In this article, the recent 
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DIABETES-INDUCED ENDOTHELIAL 
DYSFUNCTION
The term endothelial dysfunction refers to a condition 
in which the endothelium loses its physiologic properties 
and shifts toward a vasoconstrictor, prothrombotic, and 
proinﬂ  ammatory state.[11] Endothelial dysfunction has 
been associated with a variety of processes, including 
hypertension, atherosclerosis, aging, heart and renal failure, 
coronary syndrome, obesity, vasculitis, infections, sepsis, 
rheumatoid arthritis, thrombosis, smoking as well as with 
type 1 and type 2 diabetes [6]
Diabetes mellitus, often simply referred to as diabetes, is 
a condition with elevated blood glucose levels, as a result 
of either the body not producing enough insulin, or 
because cells do not properly respond to the insulin that is 
produced. The latter condition is characterized by fasting 
hyperglycemia and by a high risk of atherothrombotic 
disorders affecting the coronary, cerebral, and peripheral 
arterial trees.[12] Despite improvement in the management 
of patients with unstable coronary syndromes, diabetes 
is still linked to a substantial increase in mortality and 
morbidity among these patients.[13] Accordingly, developing 
new therapies for the treatment of diabetic patients is of 
great clinical importance.[14,15]
In diabetes, dysfunction of the vascular endothelium is 
regarded as an important factor in the pathogenesis of 
diabetic micro- and macroangiopathy.[8] There are three 
main sources contributing to endothelial dysfunction in 
diabetes: (1) hyperglycemia and its immediate biochemical 
sequelae directly alter endothelial function; (2) high glucose 
(HG), which influences endothelial cell functioning 
indirectly by the synthesis of growth factors and vasoactive 
agents in other cells and alters endothelial monolayer 
permeability; and (3) the components of the metabolic 
syndrome that can affect endothelial function.[8]
There are many signaling molecules involved in the 
pathogenesis of endothelial dysfunction. In the following 
paragraphs, recent studies on this topic, mainly focusing 
on the roles of arginase and reactive oxygen species (ROS), 
protein kinase C (PKC), and tumor necrosis factor (TNF), 
are addressed.
ROLE OF ARGINASE AND REACTIVE OXYGEN 
SPECIES IN DIABETES-ASSOCIATED 
ENDOTHELIAL DYSFUNCTION
Conditions contributing to diabetic vascular remodeling 
and dysfunction include the effects of oxidative stress 
and decreased NO bioavailability.[16-19] NO production 
by endothelial NOS (eNOS) is critically involved in 
maintaining the integrity and stability of the vascular 
endothelium, preventing platelet aggregation and leukocyte 
adhesion, and maintaining blood ﬂ  ow.[20] Availability of the 
semi-essential amino acid L-arginine is required for eNOS 
activity and NO production and is therefore essential for 
vascular integrity and function. Arginase is a hydrolytic 
enzyme, which converts L-arginine into urea and ornithine 
and exists as 2 isoforms: arginase I and II.[21] Whereas 
arginase I is a cytosolic enzyme, expressed at high levels in 
the liver, arginase II is a mitochondrial enzyme expressed 
primarily in the extrahepatic tissues, especially in the kidney. 
Knockdown of arginase I has been shown to restore NO 
signaling in the vasculature of old rats.[22] Both arginase I 
and II have been found in endothelial cells, arginase I being 
the dominant isoform.[23] 
Arginase and eNOS compete for their common substrate, 
L-arginine. As such, increased arginase activity can lead to 
eNOS dysfunction.[23,24] We have shown that hepatic and 
vascular arginase activity is increased in diabetic rats and 
that arginase I expression and activity are increased in aortic 
endothelial cells exposed to HG.[24] TNF has also been 
shown to induce arginase activity.[25] Furthermore, arginase 
actions causing endothelial dysfunction, as indicated by 
decreased NO availability, are blocked by the Rho kinase 
inhibitor Y-27632.[26] Additionally, an inhibitor of arginase 
reversed diabetes-induced endothelial dysfunction in the 
coronary vessels of diabetic rats.[24] Also, arginase was 
found to mediate retinal inﬂ  ammation in lipopolysaccharide 
(LPS)-induced uveitis.[21]
Taken together, these ﬁ  ndings[21-26] suggest that arginase and 
RhoA may be mediators of diabetes-induced inﬂ  ammatory 
effects in vascular disease. Apart from arginase, ROS also 
play an important role in vascular dysfunction in diabetes, 
although the source of their generation remains elusive. 
Overproduction of superoxide can lead to scavenging of 
NO and to its reduced bioavailability.[27,28] ROS have been 
implicated in increased arginase activity and expression. 
Indeed, arginase activation can cause uncoupling of eNOS 
by reducing the supply of L-arginine. The uncoupled eNOS 
uses molecular oxygen to produce superoxide, thereby 
further reducing NO and increasing ROS formation 
[Figure 1].
IMPLICATION OF PROTEIN KINASE C
An important glucose-induced alteration in cellular 
metabolism that may account for endothelial dysfunction 
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is activation of PKC. Hyperglycemia causes de novo 
synthesis of diacylglycerol, leading to the activation of 
PKC, a pathway now demonstrated in all vascular tissues 
involved in diabetic complications.[29] Of interest, the 
adverse effects of elevated glucose levels on acetylcholine-
induced relaxation of rabbit aorta and rat pial arterioles 
were restored by the addition of PKC-inhibitors.[30,31] 
Diabetes-induced translocation of PKC-alpha to renal 
membranes was associated with increased nicotinamide 
adenine dinucleotide phosphate oxidase-dependent 
superoxide generation.[32] It has been proposed that HG 
concentrations rather specifically activate the beta II 
isoform of PKC.[33] However, the PKC alpha isoform, 
which is activated by HG in bovine aortic endothelial 
cells, has also been suggested to play an important role 
in diabetes mellitus-associated endothelial dysfunction, 
since specific antisense or pharmacologic inhibition 
completely abolished the effects of HG on endothelial 
cell permeability.[34] The reported activity of PKC-alpha 
on endothelial permeability is at least partially mediated by 
inducing phosphorylation of p115RhoGEF,[35] a guanine 
nucleotide exchange factor (GEF) for Rho GTPase.[36] 
Because active RhoA is implicated in arginase induction,[24] 
it suggests that PKC-alpha might also be involved in 
regulation of arginase activity.
TUMOR NECROSIS FACTOR: A MOONLIGHTING 
CYTOKINE IN ENDOTHELIAL DYSFUNCTION
Human TNF is a 51-kDa homotrimeric protein. TNF is 
generated as a membrane-bound precursor that is cleaved 
by the metalloproteinase family member TNF-alpha 
converting enzyme, giving rise to the soluble protein.[37] The 
main sources of the cytokine are activated macrophages 
and T cells. TNF binds to 2 different TNF receptors, 
TNF-R1 (55 kDa) and TNF-R2 (75 kDa), at least one of 
which is expressed in most somatic cells.[37] Soluble TNF 
has the highest afﬁ  nity for TNF-R1, whereas membrane-
bound TNF preferentially interacts with TNF-R2.[38] Apart 
from the ligand TNF, also the receptors exist as membrane-
associated and soluble forms.[37] TNF-R1, but not TNF-R2, 
contains a death domain, which signals apoptosis upon 
the formation of the death-inducing signaling complex[37] 
Although not carrying a death domain, TNF-R2 has 
nevertheless been implicated in apoptosis regulation in 
microvascular endothelial cells.[39] 
Spatially distinct from its receptor binding sites, TNF 
carries a lectin-like domain, recognizing specific 
oligosaccharides, such as N,N′-diacetylchitobiose and 
branched trimannoses,[40] which can be mimicked by the 
17-amino acid circular TIP peptide (amino acid sequence: 
CGQRETPEGAEAKPWYC).[41] Three residues, namely, 
T105, E107, and E110, appear to be crucial for this activity. 
The TIP peptide exerts a lytic activity toward bloodstream 
forms of African trypanosomes,[41] which occurs upon 
binding to the oligosaccharides expressed in the variant-
speciﬁ  c glycoprotein of the parasites. More importantly, 
the TIP peptide also increases sodium transport in lung 
microvascular endothelial cells.[42] Interestingly, the activities 
of the lectin-like domain of TNF cannot be inhibited by 
the soluble TNF receptors.[41] 
TNF is one of the key inﬂ  ammatory mediators that is 
expressed during a variety of inﬂ  ammatory conditions 
and initiates the expression of an entire spectrum of 
inﬂ  ammatory cytokines ranging from many interleukins 
to interferons.[43] It is suggested that inﬂ  ammation is an 
effector of not only endothelial dysfunction, but also insulin 
resistance and atherosclerosis.[44] Under inflammatory 
conditions, TNF can increase the expressions of adhesion 
molecules, such as vascular cell adhesion molecule (VCAM-
1) and intercellular adhesion molecule (ICAM-1); and as 
such promote the adherence of monocytes.[45] Moreover, 
TNF can affect NO production by decreasing eNOS 
expression[46] and increase the production of ROS in 
neutrophils and endothelial cells through NAPH oxidase,[47] 
xanthine oxidase,[48] and uncoupled NOS.[49] The pivotal 
role of TNF in diabetes-induced endothelial dysfunction 
can also be manifested by the observation that endothelial 
function is close to normal in a TNF-knockout diabetic 
mouse model.[50] 
The generation of TNF is increased during diabetes, and 
the cytokine has been shown to upregulate the expression 
of arginase in endothelial cells, which leads to endothelial 
dysfunction during ischemia reperfusion injury in mice.[25] 
Figure 1:  Mechanisms leading to endothelial dysfunction in diabetes
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Recent studies have indicated that TNF can affect 
endothelial barrier integrity.[51] by means of (1) inducing 
apoptosis of lung microvascular endothelial cells,[39] which 
can contribute to the disruption of the endothelial barrier 
during acute lung injury and acute respiratory distress 
syndrome;[52] (2) by inducing the production of ROS;[53] 
and (3) by directly increasing endothelial permeability in a 
RhoA/ROCK-dependent manner.[54] PKC-alpha activation 
was proposed to be involved in TNF-mediated increases 
in permeability of pulmonary microvessel endothelial 
monolayers.[55] On the other hand, the lectin-like domain of 
TNF, mimicked by the TIP peptide, can increase endothelial 
monolayer resistance in the presence of bacterial toxins, 
by means of inhibiting listeriolysin-induced PKC-alpha 
activation, which in turn inhibits RhoA activation and 
myosin light chain phosphorylation.[56] Moreover, the lectin-
like domain of TNF can reduce ischemia-reperfusion–
induced ROS generation in a lung transplantation model[57] 
As such, the lectin-like domain of TNF can potentially 
oppose the deleterious receptor-mediated activities of the 
cytokine on the endothelium.[58]
CONCLUSION
The present communication has reviewed some recent 
studies on diabetes-induced endothelial dysfunction and has 
discussed the important roles of arginase, PKC and TNF in 
this complicated pathological condition. The interactions 
between these molecules and the proposed mechanism of 
diabetes-induced endothelial dysfunction are summarized 
in Figure 1. New insights into these mechanisms and into 
crucial targets of endothelial dysfunction in diabetes may 
lead to novel strategies for treatment in the future. 
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